IT Dept searches offices, manufacturing facilities of Akums Drugs, its subsidiaries

Published On 2025-01-23 10:12 GMT   |   Update On 2025-01-23 10:13 GMT

IT Dept searches Akums Drugs, it subsidiaries offices

New Delhi: The Income Tax Department has searched the offices and manufacturing units of a contract development and manufacturing organisation (CDMO) Akums Drugs and Pharmaceuticals Limited and its subsidiaries, the company informed in a recent BSE filing.

The search was conducted under the Income Tax Act, 1961.

"We have fully cooperated with the officials of IT Department during the search and responded to the clarifications and details sought by them. We will continue to provide any further clarification/information that may be required," the Company stated..

Read also: Akum Drugs & Pharmaceutical gets CDSCO Panel nod for BE study of FDC Eplerenone plus Torsemide film-coated tablet

Further, Akum stated, "Akums is a law-abiding Company and follows the best corporate governance practices," it added.

"We have extended our full cooperation to the officials of the IT Department in this regard. The business operations of the Company continue as usual except some minor hiccups. We will comply with legal obligation in relation to disclosure(s) from time to time," it added.

Read also: Akums Drugs ink pact with global pharma firm for production, supply of pharma formulations in European market

Established in 2004, Akums is a Contract Development and Manufacturing Organization (CDMO). In FY23, Akums captured a 9.3% market share by value in the Indian domestic CDMO market, with an 8.8% share by volume in the Indian Pharmaceutical Market (IPM). By FY24, its market share by value increased to 10.0%, with a significant 30.2% share by value within the domestic CDMO market. Akums operates 15 state-of-the-art facilities producing a wide range of modern dosage forms across multiple therapeutic segments.

The company offers a comprehensive suite of advanced services, including formulation development, bioequivalence studies, clinical trials, and securing Drug Controller General of India (DCGI) approvals for manufacturing and marketing new Fixed Dose Combinations (FDCs) and molecules.

Read also: Income Tax dept imposes Rs 2.3 crore penalty on Torrent Pharma

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News